Physician profile
Manila Kumar
NPI 1942739784
$917.52
in general payments reported to CMS, 2019-2025
18 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $355 · 2024: $162 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.86 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $226.24 | 2022-2025 | |
| Celgene Corporation | $117.46 | 2022-2024 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $108.10 | 2022-2024 | Soliris |
| Amgen INC. | $66.01 | 2022 | |
| Daiichi Sankyo INC. | $58.08 | 2025 | Vanflyta |
| Pharmaessentia USA Corporation | $45.65 | 2022 | |
| Genzyme Corporation | $44.67 | 2022 | |
| Eisai INC. | $32.64 | 2025 | |
| Genmab U.S., INC. | $31.21 | 2024-2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $29.00 | 2025 | Clonoseq |
| Abbvie INC. | $28.22 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.53 | 2025 | Libtayo |
| Beigene USA, INC. | $20.56 | 2022 | |
| Janssen Biotech, INC. | $20.10 | 2025 | |
| Tempus Ai, INC | $18.97 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $16.99 | 2022 | |
| Exelixis INC. | $15.70 | 2025 | Cabometyx |
| Genentech USA, INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manila Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.